Point Of Care | PoC Diagnostics Market To Be Worth Over $30.9 Billion By 2024
Point of Care (POC) testing is
medical diagnostic testing performed outside the clinical laboratory in close
proximity to where the patient is receiving care. It is typically performed by
non-laboratory personnel and the results are used for clinical decision making.
The factors such as rising prevalence of diseases resulting in subsequent
increase in demand for better treatment and rapid diagnostic services, and
staff shortages in clinical laboratories are primarily driving the demand for
POC diagnostics.
![]() |
| PoC Diagnostics Market |
The report states
that lateral flow assays (immunochromatography tests/lateral flow immunoassays)
platform accounts for the largest share of the total point of care diagnostics
market. However, point of care molecular diagnostics tests are expected to grow
at a fastest CAGR of 13.3% from 2018 to 2024. Meticulous Research® anticipated as to why
this area is emerging as the largest use of the platform: “The shift from the
traditional microbiology-based testing to molecular testing stems from the
rising antibiotic resistance crisis, and faster turnaround time of POC
molecular assay tests.”
Browse in-depth Report on - https://www.meticulousresearch.com/product/point-of-care-diagnostics-poc-market/
Over-the-Counter
(OTC) testing is cited as the major trend driving the growth of point of care
diagnostics market. OTC testing kits are expected to generate relatively higher
revenue than prescription tests over the forecast period owing to the
associated ease of usage, growing home care and self-testing, and higher
availability and greater adoption rate.
On the basis of
product type, blood glucose monitoring testing currently dominates the global
POC diagnostics market; however, infectious diseases testing kits segment is
expected to register growth during the forecast period. Influenza causes
12,000- 50,000 deaths annually in the U.S. Rapid testing for influenza A and B
allows for accurate and timely treatment, as patients only have a 48-hour
window to receive critical antiviral therapy. Thus, growing prevalence of
infectious diseases and need for rapid testing and treatment provide robust
opportunities for POC testing companies like BD, Quidel, Roche, and Alere (Abbott).
Meticulous Research® help
companies operating in POC diagnostics market to identify key growth segments
to invest in.
Request for a sample of this research
report @ -https://www.meticulousresearch.com/download-sample-report/cp_id=4871
Finally, the report
states that North America is currently the home of most of the point of care
diagnostics companies. However, Asia-Pacific is named as the area expected to
grow most by 2024. Major reasons cited for this rising demand include
accelerated growth of the economies; relatively lower availability of
sophisticated central laboratory testing services; a larger population base in
need for clinical testing; increasing incidence of infectious and
non-communicable diseases in aging population; and improving availability and
awareness of POC tests.
The key players
operating in the global point of care diagnostics market are Abbott
Laboratories, AccuBioTech Co., Ltd., Becton Dickinson and Company, Chembio
Diagnostic Systems, Inc., Danaher Corporation, EKF Diagnostics Holdings plc,
WerfenLife, S.A., Johnson and Johnson Service, Inc., Nova Biomedical, F.
Hoffmann-La Roche Ltd, Sekisui Diagnostics LLC, Quidel Corporation, Siemens AG,
and Trinity Biotech, among others.
Contact Info:
Meticulous Market Research Pvt. Ltd.
Khushal
Contact Sales- +91-744-7780008

Comments
Post a Comment